Immix Biopharma, Inc. (IMMX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$23.93M | -64.0% |
| 2024 | -$14.60M | -28.3% |
| 2023 | -$11.37M | -53.5% |
| 2022 | -$7.41M | -366.1% |
| 2021 | -$1.59M | -292.7% |
| 2020 | -$404.7K | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$23.93M | -64.0% |
| 2024 | -$14.60M | -28.3% |
| 2023 | -$11.37M | -53.5% |
| 2022 | -$7.41M | -366.1% |
| 2021 | -$1.59M | -292.7% |
| 2020 | -$404.7K | — |